/PRNewswire/ The age-related macular degeneration (AMD) therapeutics market will be driven by factors such as the high prevalence of AMD. The prevalence of.
DelveInsight's analysts estimate that the Fuchs Endothelial Corneal Dystrophy market is expected to show positive growth, mainly attributed to increased prevalence and the anticipated launch
Ophthalmology Market Research Report by Diseases (Age-Related Macular Degeneration, Cataract, and Glaucoma), Product Type, End User, Region (Americas,.
Belite Bio has filed to raise an undisclosed amount in an IPO. The firm is developing treatment candidates for eye diseases. Read more about BLTE's IPO here.